FIRST PATIENT DOSED IN CITRYLL'S PHASE IIA HIDRADENITIS SUPPURATIVA TRIAL Multi-center, randomized study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with hidradenitis suppurativa Marks the start of the second Phase IIa trial to evaluate first-in-class monoclonal antibody CIT-013 this year, following the rheumatoid arthritis trial Oss, Netherlands – 08 December […]
(Euronext Amsterdam:SHELL),(LSE:SHEL),(NYSE:SHEL), SHELL PLC THIRD QUARTER 2025 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS December 8, 2025 The Board of Shell plc today announced the pounds sterling and euro equivalent dividend payments in respect of the third quarter 2025 interim dividend, which was announced on October 30, 2025 at US$0.358 per ordinary share. Shareholders have been
(LSE:MICC),(Euronext Amsterdam:MICC),(NYSE:MICC), Advertisement THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM CANADA, SWITZERLAND OR INDIA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE UNLAWFUL. Amsterdam, The Netherlands 8 December 2025 The Magnum Ice Cream Company announces admission to trading on Euronext
BASINGSTOKE, United Kingdom, Dec. 08, 2025 (GLOBE NEWSWIRE) — A new study by global tech strategists Juniper Research has found that the number of customer interactions automated by AI agents will grow from 3.3 billion interactions in 2025 to more than 34 billion by 2027. This surge of 1,000% over the next two years is
ING reports outcome of 2025 EU-wide transparency exercise GlobeNewswire December 08, 2025 ING reports outcome of 2025 EU-wide transparency exercise ING Group acknowledges the announcement from the European Banking Authority (EBA) and the European Central Bank (ECB) regarding the 2025 EU-wide Transparency Exercise. The EBA Board of Supervisors approved the package for the EUâ€wide Transparency
FIRST PATIENT DOSED IN CITRYLL'S PHASE IIA HIDRADENITIS SUPPURATIVA TRIAL GlobeNewswire December 08, 2025 FIRST PATIENT DOSED IN CITRYLL'S PHASE IIA HIDRADENITIS SUPPURATIVA TRIAL Multi-center, randomized study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with hidradenitis suppurativa Marks the start of the second Phase IIa trial to evaluate first-in-class monoclonal
Initial admission to the Official List GlobeNewswire December 08, 2025 Advertisement THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM CANADA, SWITZERLAND OR INDIA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE UNLAWFUL. Amsterdam, The Netherlands 8 December 2025 The Magnum Ice
EpiEndo Pharmaceutical's ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patients GlobeNewswire December 08, 2025 ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patients Glasmacinal, a novel macrolide, was well tolerated and reduced neutrophilic inflammation in COPD patients. Glasmacinal had no detectable impact on the
SHELL PLC THIRD QUARTER 2025 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS GlobeNewswire December 08, 2025 SHELL PLC THIRD QUARTER 2025 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS December 8, 2025 The Board of Shell plc today announced the pounds sterling and euro equivalent dividend payments in respect of the third quarter 2025 interim dividend, which was
AI Agents to Power 1,000% More Customer Interactions for Enterprises Globally by 2027 GlobeNewswire December 08, 2025 BASINGSTOKE, United Kingdom, Dec. 08, 2025 (GLOBE NEWSWIRE) — A new study by global tech strategists Juniper Research has found that the number of customer interactions automated by AI agents will grow from 3.3 billion interactions in 2025